

Medical Necessity Guidelines Skysona (elivaldogene autotemcel)

Policy Number: 065

Contents

Overview.....	1
Medicare Advantage	1
Mass General Brigham ACO	3
One Care and Senior Care Options (SCO).....	3
Commercial and Qualified Health Plans.....	3
Codes	3
Summary of Evidence	3
Effective Dates.....	4
References.....	4

Overview

Skysona is an autologous hematopoietic stem cell (HSC)-based gene therapy indicated to slow the progression of male patients with confirmed early, active cerebral adrenoleukodystrophy (CALD).

Medicare Advantage

Prior Authorization Required	Yes ☒ No ☐
------------------------------	---

Mass General Brigham Health Plan uses guidance from the Centers for Medicare and Medicaid Services (CMS) for medical necessity determinations for its Medicare Advantage plan members. National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), Local Coverage Articles (LCAs), and documentation included in the Medicare manuals are the basis for medical necessity determinations. When there is no guidance from CMS for the requested service, Mass General Brigham Health Plan's medical policies are used for medical necessity determinations. **At the time of Mass General Brigham Health Plan's most recent policy review, Medicare had:**

- [Medicare Benefit Policy Manual Chapter 15: Covered Medical and Other Health Services](#)

When CMS documentation references FDA labeling, Mass General Brigham Health Plan develops coverage criteria to clarify medical necessity of the requested services. Mass General Brigham Health Plan coverage criteria align with FDA labeling without contradicting existing determinations and enhance the clarity of medical necessity requirements, documentation requirements, and clinical indications.

Criteria

A. Criteria for Initial Approval

Authorization of a single treatment may be granted to male members 4 to 17 years of age for treatment of early, active cerebral adrenoleukodystrophy (CALD) when **ALL** of the following criteria are met:

1. Documentation of adrenoleukodystrophy as established by meeting BOTH of the following:

- a. Elevated plasma very long chain fatty acid levels according to the standard reference values of the performing laboratory.
 - b. The presence of a variant in the ABCD1 gene as detected by genetic testing.
 - 2. Documentation of early, active CALD as defined by meeting ALL of the following:
 - a. A Loes score between 0.5 and 9 (inclusive) on the 34-point scale.
 - b. A Neurologic Function Score (NFS) less than or equal to 1.
 - c. Gadolinium enhancement on MRI of demyelinating lesions.
 - 3. The member is eligible for a hematopoietic stem cell transplant (HSCT) but an HLA-matched family donor is not available. HLA matching with family members should be explored to optimally inform transplant planning.
 - 4. The member tests negative for HIV-1 and HIV-2 in accordance with clinical guidelines before collection of cells for manufacturing.
 - 5. The member has been evaluated for hepatic function to ensure HSC transplantation is appropriate as defined by one of the following:
 - a. Alanine transaminase (ALT) value less than 2.5x the upper limit of normal (ULN), or
 - b. Aspartate transaminase (AST) value less than 2.5x ULN, or
 - c. Total bilirubin value less than 3.0 milligram per deciliter (mg/dL), except if there is a diagnosis of Gilbert's Syndrome, and the member is otherwise stable.
 - 6. The member has been evaluated for renal impairment to ensure HSC transplantation is appropriate.
 - 7. If the member has isolated pyramidal tract disease, a statement from the treating physician explaining why the benefits of Skysona outweigh the risks is required.
- B. Dosing and Administration**
- 1. The recommended dose is a single dose, given intravenously, containing a minimum of 5.0×10^6 CD34+ cells/kg of body weight in which body weight is based on individual's weight prior to first apheresis.
 - 2. Full myeloablative and lymphodepleting conditioning must be administered before infusion of Skysona.
- C. Duration of Therapy**
- 1. Single treatment course
 - 2. The member should receive seizure, hepatic veno-occlusive disease, anti-fungal, and antibiotic prophylaxis as needed.
- D. Facility Criteria**
- 1. The medication is prescribed by a hematologist, a neurologist, and/or a stem cell transplant specialist
 - 2. The treatment will be administered at a Skysona Qualified Treatment Center.

Exclusions



1. The member has a full deletion of the ABCD1 gene; or
2. The member has CALD resulting from head trauma; or
3. The member received any vaccines within the six weeks prior to the start of myeloablative conditioning or will receive vaccines prior to conclusion of hematological recovery; or
4. The member has taken anti-retroviral medications in the month preceding initiation of medications for stem cell mobilization or will take them prior to completion of all apheresis cycles; or
5. For a member capable of fathering a child, they refuse to use effective contraception from the start of mobilization through at least 6 months after administration of Skysona; or
6. The member is younger than 4 years of age; or
7. The member has previously received Skysona or another gene therapy treatment.

Mass General Brigham ACO

Prior Authorization Required	Yes ☒ No ☐
------------------------------	---

Prior authorization requests for Skysona for Mass General Brigham ACO members should be submitted to the MassHealth Drug Utilization Review Program. Criteria for Skysona are found in [Table 72: Agents not Otherwise Classified](#).

One Care and Senior Care Options (SCO)

Prior Authorization Required	Yes ☒ No ☐
------------------------------	---

Mass General Brigham Health Plan uses guidance from CMS for medical necessity determinations for its One Care and SCO plan members. NCDs, LCDs, LCAs, and documentation included in the Medicare manuals are the basis for medical necessity determinations. When there is no guidance from CMS for the requested service, or the member does not meet the medical necessity criteria for the requested service, Mass General Brigham Health Plan uses medical necessity guidelines from MassHealth. **See Medicare Advantage criteria and exclusions above. If Medicare Advantage criteria are not met, then MassHealth criteria are applied.**

Commercial and Qualified Health Plans

Prior Authorization Required	Yes ☒ No ☐
------------------------------	---

Prior authorization for Skysona for Commercial and Qualified Health Plan members is managed by Prime Therapeutics. See the [Prime Therapeutics policy for Skysona](#) for more information.

Codes

The following codes are included below for informational purposes only; inclusion of a code does not constitute or imply coverage or reimbursement.

Authorized Code	Code Description
J3387	Injection, elivaldogene autotemcel, per treatment

Summary of Evidence

Elivaldogene autotemcel (Skysona, eli-cel), a lentiviral gene therapy developed by Bluebird Bio, received FDA accelerated approval in September 2022 for the treatment of early, active cerebral adrenoleukodystrophy



(CALD), a rare and fatal neurodegenerative disease. The pivotal STARBEAM (ALD-102) study evaluated eli-cel in a Phase 2/3 single-arm, open-label trial of boys aged ≤ 17 years with early-stage CALD. In this study, eli-cel was administered following conditioning with busulfan-cyclophosphamide. The initial report, by Eichler et al. (2017), reported on the first 17 patients, aged 4-13 (median 6). The study achieved its primary endpoint of major functional disability (MFD)-free survival, with a median follow-up of 29.4 months showing sustained disease stabilization in 94% of evaluable participants. A subsequent report of the same study, by Eichler et al. (2024), included 32 patients. Of those, 91% survived 24 months with no major functional disabilities, and at the most recent follow-up (median 60.2 months) 81% survived with no major functional disabilities. A second phase 2-3 study of the same agent, ALD-104, is in process and has not yet reported efficacy outcomes. The treatment protocol in ALD-104 differed from that of ALD-102 in that 104 used busulfan-fludarabine as the conditioning regimen, used plerixafor mobilization consistently, and used a fixed dose of transducing viral particles relative to host cells (Duncan et al. 2024).

Despite the promising early efficacy data, recent reports of hematologic malignancy caused by insertional oncogenesis have raised major safety concerns. As reported by Duncan et al. (2024), 6 cases of myelodysplastic syndrome and 1 case of acute myeloid leukemia developed between 14-92 months post-treatment among 67 patients enrolled in the ALD-102 and ALD-104 studies, including 1/32 in ALD-102 and 6/35 in ALD-104. The malignant cells showed evidence of clonal vector insertion within oncogenes and clonal evolution with acquisition of somatic genetic defects. It has been hypothesized that the oncogenesis is related to the strong viral MND promoter used in eli-cel, and perhaps also to the profound immune suppression caused by fludarabine (Dunbar 2024). Other adverse events have included myelosuppression, infections, and immune-related complications; a REMS and black-box warning are in effect.

Based on these safety concerns, and the fact that long-term safety beyond 5 years remain unknown, consensus guidelines recommend allogeneic stem cell transplantation, rather than lentiviral gene therapy for most patients with early-stage CALD (Engelen M, et al. 2022). Eli-cel may still have a role, particularly for patients for whom no appropriate HLA-matched donor can be identified. Mass General Brigham Health Plan considers eli-cel medically necessary for members without an appropriate donor and who otherwise meet inclusion criteria consistent with those in the pivotal trial reported by Eichler (2017).

Effective Dates

December 1, 2026: Annual review. Rearranged criteria and added a requirement that the member be screened for renal insufficiency per the package insert. References updated.

April 2026: Ad hoc review. Reformatted policy. Clarified Medicare Advantage section and hierarchy of criteria in One Care and SCO section. Added Prime Therapeutics information to Commercial and Qualified Health Plans section. Updated code list.

January 2026: Ad hoc review. Updated prior authorization table and added variation for One Care and SCO members.

October 2025: Annual review. Fixed code disclaimer.

April 2025: Ad hoc review. MassHealth variation updated to include new prior authorization process.

March 2025: Ad hoc review. Summary of Evidence added. References updated.

October 2024: Annual review. Codes updated. Code disclaimer added.

September 2024: Ad hoc review. Added MassHealth variation. Fixed Medicare variation language. References updated.

May 2023: Effective date.

References

Bluebird bio, Inc. bluebird bio receives FDA accelerated approval for Skysona gene therapy for early, active cerebral adrenoleukodystrophy (CALD). Press Release. Somerville, MA: bluebird bio; September 16, 2022a



Dunbar CE. Weighing the risks of lentiviral gene therapy for cerebral adrenoleukodystrophy. *NEJM* 2024;391(14):1358-9.

Duncan CN, Bledsoe JR, Grzywacz B, et al. Hematologic cancer after gene therapy for cerebral adrenoleukodystrophy. *NEJM* 2024;391(14):1287-301.

Eichler F, Duncan C, Musolino PL, et al. Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy. *N Engl J Med*. 2017 Oct 26;377(17):1630-1638. doi: 10.1056/NEJMoa1700554. Epub 2017 Oct 4. PMID: 28976817; PMCID: PMC5708849

Eichler F, Duncan CN, Musolino PL, et al. Lentiviral gene therapy for cerebral adrenoleukodystrophy. *NEJM* 2024;391(14):1302-12.

Engelen M, Kemp S, de Visser M, et al. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. *Orphanet J Rare Dis*. Aug 13 2012; 7: 51. PMID 2288915

Engelen M, van Ballegoij WJC, Mallack EJ, et al. International Recommendations for the Diagnosis and Management of Patients with Adrenoleukodystrophy: A Consensus-Based Approach. *Neurology*. Nov 22 2022; 99(21): 940-951. PMID 3617515

Executive Summary: X-linked adrenoleukodystrophy (X-ALD) to the Recommended Uniform Screening Panel. Available at <https://www.hrsa.gov/sites/default/files/hrsa/advisorycommittees/heritable-disorders/rusp/x-ald-exsum.pdf>. Last accessed March 30, 2023.

Kemper AR, Brosco J, Comeau AM, et al. Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation. *Genet Med*. Jan 2017; 19(1): 121-126. PMID 27337030

Mallack EJ, Turk BR, Yan H, et al. MRI surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: Meta-analysis and consensus guidelines. *J Inherit Metab Dis*. May 2021; 44(3): 728-739. PMID 33373467

Skysona [package insert]. Somerville, MA. Bluebird Bio; August 2025.

